Cue Biopharma's average one-year price target was revised sharply higher to $122.40 per share from $4.08, a 2,900% increase. The change reflects a significant upward shift in analyst expectations for the biotech name. While highly positive for sentiment, the article is purely an estimate update and is unlikely to have broad market impact.
Cue Biopharma's average one-year price target was revised sharply higher to $122.40 per share from $4.08, a 2,900% increase. The change reflects a significant upward shift in analyst expectations for the biotech name. While highly positive for sentiment, the article is purely an estimate update and is unlikely to have broad market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
